The COVID Project
The record
- Jurisdiction
- United States (federal); Drug Enforcement Administration, Diversion Control Division
- Level
- Federal
- Authority
- 21 U.S.C. 802(54)(D), 829; 21 C.F.R. 1306.04-.11
- Issued
- 2020-03-31 Mar. 31, 2020
- Effective
- 2020-03-31
- End
- For the duration of the public health emergency, unless DEA specifies an earlier date (read as 2021-09-30)
- In force
- Mar. 31, 2020 to Sept. 30, 2021
- Quarters
- 2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3
2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3
- Limitation types
- Telework mandateHealth care ordersOther
- Addressees
- DEA-registered practitioners
- pharmacies
- Functions reached
- TM telehealth
- CL clinical
- RT pharmacy
- Collection
- Other federal health agencies AGY-FED-HEALTH-OTHER
Operative words
In response to the COVID-19 public health emergency declared by the Secretary of Health and Human Services, the Drug Enforcement Administration (DEA) has adopted policies to allow DEA-registered practitioners to prescribe controlled substances without having to interact in-person with their patients. These policies are effective beginning March 31, 2020, and will remain in effect for the duration of the public health emergency, unless DEA specifies an earlier date.
Enforcement
Prescribing outside the stated policies unlawful under 21 U.S.C. 829 and 841-843
Notes
DEA's own consolidated statement of the telemedicine, telephone, email and pharmacy-transmission methods permitted in the emergency.